Business Wire

GA-ASI Awarded FMS Development Contract for MQ-9B PROTECTOR

Del

General Atomics Aeronautical Systems, Inc. (GA-ASI) is pleased to announce the recent award of a $81M Foreign Military Sales contract by the US Air Force Life Cycle Management Center for the United Kingdom (UK) MQ-9B PROTECTOR unmanned aircraft system programme. This contract provides for integration and component level testing for UK specific enhancements to support the MQ-9B PROTECTOR programme. GA-ASI performed the first flight of the MQ-9B configuration less than two years ago, and the Remotely Piloted Aircraft (RPA) has continued to meet a series of key qualification milestones.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180408005029/en/

MQ-9B is the “Certifiable” (STANAG 4671) version of GA-ASI’s MQ-9 Predator® B product line. It can m ...

MQ-9B is the “Certifiable” (STANAG 4671) version of GA-ASI’s MQ-9 Predator® B product line. It can meet the stringent airworthiness certification requirements of various military and civil authorities, including the UK Military Airworthiness Authority (MAA) and the US FAA. (Photo: Business Wire)

MQ-9B is the “Certifiable” (STANAG 4671) version of GA-ASI’s MQ-9 Predator® B product line. Its development is the result of a five-year, company-funded effort to deliver a RPA that can meet the stringent airworthiness certification requirements of various military and civil authorities, including the UK Military Airworthiness Authority (MAA) and the US FAA. MQ-9B is the latest evolution of the multi-mission Predator B fleet. GA-ASI named its baseline MQ-9B SkyGuardian™, and the maritime surveillance variant, SeaGuardian.

“MQ-9B represents the next generation of RPA system capabilities,” said Linden Blue, CEO, GA-ASI. “It has demonstrated new airborne endurance records (>48 hours) and automatic takeoffs and landings under SATCOM-only control. MQ-9B will also have our currently operational MQ-9 detect and avoid system (with collision-avoidance radar), which will support MQ-9B operations in civil airspace.”

Other important MQ-9B milestones were achieved in 2017, including the first FAA-approved flight for a company-owned RPA through non-segregated airspace without a “chase aircraft,” when the RPA flew from Yuma, Arizona to Gray Butte, California in August 2017.

Upcoming aircraft qualification milestones include lightning protection tests, which are expected within the next 60 days. The aircraft system’s overall qualification schedule remains on track.

A weaponized variant of the system is being acquired by the Royal Air Force (RAF) under the UK’s MQ-9B PROTECTOR programme. The MQ-9B PROTECTOR will fly in excess of 40 hours with airspeeds up to 210 knots, reach altitudes of more than 40,000 feet, and carry 4750lbs (2159 kg) of external payload.

“The UK MOD and RAF are pleased with the progress of their MQ-9B PROTECTOR programme and work continues at pace on the certification aspects of this platform, ahead of achieving a full Military Type Certificate as the platform enters service. Recently-reported Protector procurement schedule adjustments reflect the UK government managing the transition between getting the most out of our current Reaper aircraft, which is helping us defeat Daesh in the Middle East, and moving to the cutting-edge Protector,” said Air Marshal Julian Young, Chief of Materiel (Air) at DE&S. “The Protector programme, which is based on GA-ASI’s SkyGuardian aircraft, is a key capability for the UK, and the MOD and GA-ASI have worked collaboratively to support programme changes, as well as continuing to meet growing interest in this unique capability.”

Hi-resolution photos of MQ-9B are available to qualified media outlets from the listed GA-ASI media contact.

About GA-ASI

General Atomics Aeronautical Systems, Inc. (GA-ASI), an affiliate of General Atomics, is a leading designer and manufacturer of proven, reliable Unmanned Aircraft Systems (UAS), radars, and electro-optic and related mission systems, including the Predator®, Reaper® and Gray Eagle UAS programs of record and the Lynx® Multi-mode Radar. Celebrating over 25 years of aviation innovation, GA-ASI provides long-endurance, multi-mission capable aircraft with integrated sensor and data link systems required to deliver persistent flight, enabling situational awareness and rapid strike. The company also produces a variety of ground control stations and sensor control/image analysis software, offers pilot training and support services, and develops meta-material antennas. For more information, visit www.ga-asi.com.

Predator, Reaper, and Lynx are registered trademarks and SkyGuardian is a trademark of General Atomics Aeronautical Systems, Inc.

Contact information

General Atomics Aeronautical Systems, Inc.
Melissa Haynes
+1 (858) 524-8108
ASI-MediaRelations@ga-asi.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Illumina and the Lundbeck Foundation GeoGenetics Centre Collaborate to Generate One of the Largest Ancient Genome Datasets to Decode the Genetic Origins and Evolution of Mental Health Issues26.3.2019 06:00:00 CETPressemelding

Illumina (NASDAQ:ILMN) and the Lundbeck Foundation GeoGenetics Centre at the University of Copenhagen, Denmark partner to explore the relationship between the evolutionary history of select mental and neurological disorders and infectious pathogens. One of the first projects of its kind worldwide, the endeavor aims to acquire new knowledge in terms of the medical and biological understanding of special factors underlying the development of human neuropsychiatric diseases through the ages. Ultimately, the project may provide a new approach to the development of medicines and other therapeutic treatments for mental and neurological conditions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190325005867/en/ Where do brain disorders come from? In an effort to shed light on the role of microbes in the pathogenesis of neuropsychiatric illnesses, such as Alzheimer’s disease and schizophrenia, Professor Eske Willerslev and his team

Earth Networks Announces Completion of Severe Weather Early Warning System for PAGASA25.3.2019 23:00:00 CETPressemelding

Earth Networks announced today the completion of the Philippines’ first nationwide severe weather monitoring and alerting network with associated software services for the Philippine Atmospheric, Geophysical, and Astronomical Services Administration (PAGASA), the National Meteorological and Hydrological Services (NMHS) agency of the Republic of the Philippines. The announcement was made at the 6th annual InterMET Asia conference in Singapore. Initiated in 2017, and formally commissioned this week, the technology partnership between PAGASA and Earth Networks is the first of its kind in the Philippines and surrounding regions, powered by a network of total lightning sensors and real-time automatic weather stations for mesoscale monitoring. Installed and operated together with Philippines partner West Point Engineering, the 10-year program includes: Real-time lightning detection powered by the Earth Networks Total Lightning Network On-the-ground weather monitoring via the Earth Networks W

Game of Thrones Winter is Coming™ Launches Worldwide25.3.2019 23:00:00 CETPressemelding

Yoozoo Games, a leading game developer and publisher, today announced the global launch of Game of Thrones Winter is Coming™ , a real-time strategy PC browser game officially licensed by Warner Bros. Interactive Entertainment under license from HBO®. The game is now available in English, with additional languages to follow. HBO, Warner Bros. Interactive Entertainment and Yoozoo Games have collaborated to recreate Westeros on a massive scale, delivering an authentic and immersive multiplayer world laid out across the Seven Kingdoms – complete with major landmarks and castles from the epic TV series. The story begins immediately following the death of Eddard Stark, when the player emerges as a new Westeros lord or lady in his stead. Strategising starts in earnest in Game of Thrones Winter is Coming as players aim to build an impenetrable base, train a victorious army and recruit faithful followers from a pool of iconic characters. As players progress, they must continue to acquire the mi

bluebird bio Statement on European Regulatory Status of LentiGlobin™25.3.2019 22:40:00 CETPressemelding

A third party press release was issued today stating that the EMA (European Medicines Agency) issued an approval for the conditional Marketing Authorization Application (MAA) for LentiGlobin™, bluebird bio’s investigational gene therapy for the treatment of transfusion dependent β-thalassemia (TDT). LentiGlobin for TDT is scheduled to be reviewed as part of the CHMP (Committee on Human Medicinal Products) meeting from March 25 – 28, however no opinion has been issued by the CHMP. If the CHMP’s opinion is issued it would then be reviewed by the European Commission (EC), which has the authority to grant approval for the use of LentiGlobin in the EU. About bluebird bio, Inc. bluebird bio is pioneering gene therapy with purpose. From our Cambridge, Mass., headquarters, we’re developing gene therapies for severe genetic diseases and cancer, with the goal that people facing potentially fatal conditions with limited treatment options can live their lives fully. Beyond our labs, we’re working

Celgene Submits Application to FDA for Ozanimod for the Treatment of Relapsing Forms of Multiple Sclerosis25.3.2019 20:30:00 CETPressemelding

Celgene Corporation (NASDAQ:CELG) today announced that the Company has submitted a New Drug Application to the U.S. Food and Drug Administration (FDA) for ozanimod for the treatment of adults with relapsing forms of multiple sclerosis (RMS). Ozanimod is an oral, sphingosine 1-phosphate (S1P) receptor modulator, which binds with high affinity selectively to S1P subtypes 1 (S1P1) and 5 (S1P5). The pivotal efficacy and safety data provided in the application result from the SUNBEAM™ and RADIANCE™ Part B phase 3, multicenter, randomized, double-blind, double-dummy, active-controlled trials. “New oral treatment options with differentiated profiles like ozanimod are needed to help address an unmet need for people with relapsing forms of MS,” said Jay Backstrom, M.D., Chief Medical Officer for Celgene. “With concurrent applications in the U.S. and EU, we look forward to advancing this promising medicine through the regulatory review process to provide a new option for the treatment of RMS in

AVLT and UKTS Announce the European Medicines Agency’s Approval of the Conditional Marketing Authorization Application for Zynteglo™ (Previously Known as Lentiglobin™) Gene Therapy for the Treatment of Transfusion Dependent Beta Thalassaemia25.3.2019 19:50:00 CETPressemelding

Associazione Veneta Lotta alla Talassemia (AVLT) and the UK Thalassaemia Society (UKTS) announced today that the European Medicines Agency (EMA) has approved bluebird bio’s application for Conditional Marketing Authorization (cMAA) of their product Zynteglo™, a gene therapy for the treatment of adolescents and adults with transfusion-dependent β-thalassaemia (TDT) who do not have a β0/β0 genotype. As a result of this marketing authorisation, Zynteglo™ is now approved for use in all European countries covered by the European Medicines Agency. Zynteglo™ has been given ‘conditional authorisation’. This means that there is more evidence to be submitted, which the company is required to provide under specific obligations. Every year, the EMA will review any new information that becomes available. “People living with transfusion-dependent β-thalassaemia have a reduced life expectancy, requiring life-long frequent blood transfusions that are life-saving but may lead to complications, includin